CN-680000-ME216-A7.pdf

AHCA CONTRACT NO. MED216

AMENDMENT NO.7

AHCA Contract No. MED216, Amendment No. 7 Page 1 of 3

THIS CONTRACT, entered into between the STATE OF FLORIDA, AGENCY FOR HEALTH CARE ADMINISTRATION, hereinafter referred to as the "Agency," and FLORIDA MEDICAL SCHOOLS QUALITY NETWORK, INC., hereinafter referred to as the "Vendor," is hereby amended as follows:

1. In accordance with Standard Contract, Section I., THE VENDOR HEREBY AGREES, Sub-Section W., Requirements of Section 287.058, Florida Statutes, Item 6., which provides for renewal of the Contract for a period that may not exceed three (3) years or the original term of the Contract, whichever is longer, both Parties hereby agree to exercise the full renewal option for a period of three (3) years, beginning January 1, 2025.

Therefore, Standard Contract, Section I, Sub-Section W., Requirements of Section 287.058, Florida Statutes, Item 5., is hereby amended to now read as follows:

This Contract shall begin July 26, 2021, and end on December 31, 2027.

2. Standard Contract, Section II., THE AGENCY HEREBY AGREES, Sub-Section A., Contract Amount, the first sentence is hereby amended to now read as follows:

To pay for contracted services according to the conditions of Attachment I, Scope of Services, in an amount not to exceed $1,347,965.00 (an increase of $250,000.00), subject to the availability of funds.

3. Attachment I, Scope of Services, Exhibit A-3, Revised Deliverables, Financial

Consequences, and Performance Standards is hereby deleted in its entirety and replaced with Exhibit A-4, Revised Deliverables, Financial Consequences, and Performance Standards, attached hereto and made a part of this Contract. All references in this Contract to Exhibit A-3, shall hereinafter also refer to Exhibit A-4.

4. Attachment II, Business Associate Agreement, is hereby deleted in its entirety and replaced with Attachment II-A, Business Associate Agreement. All references to Attachment II, Business Associate Agreement, shall hereinafter refer to Attachment II- A, Business Associate Agreement.

5. Attachment V, Agency Approved Modifications and Additions for State University and College Contracts for FY 2021-2022 header, is hereby deleted in its entirety and shall read as follows:

Agency Approved Modifications and Additions for State University and College Contracts

6. Attachment V, Item 13, is hereby modified to now read as follows:

Attachment I, Scope of Services, Section X., Information Technology, Sub-Section I shall be modified by adding the following language:

The Vendor agrees to create a box folder that is specific to the university to protect information and data received for all deliverables, reports and projects for this contract.

The Vendor shall ensure access to the university’s box folder is controlled and limited to essential personnel. The Vendor will ensure all data is deleted, if feasible, no later than ten (10) years after the completion of each deliverable, except for the summary data sheets. Vendor shall maintain such data in secure manner with appropriate security

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Amendment No. 7 Page 2 of 3 controls. The Vendor shall continue to establish an ongoing open dialogue to review each project on a case-by-case basis to ensure appropriate security controls are always deployed and aligned with the specific future dataset requirements.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Amendment No. 7 Page 3 of 3

All provisions not in conflict with this Amendment are still in effect and are to be performed at the level specified in this Contract.

This Amendment and all its attachments are hereby made a part of this Contract.

This Amendment cannot be executed unless all previous Amendments to this Contract have been fully executed.

IN WITNESS WHEREOF, the Parties hereto have caused this twenty-four (24) page Amendment to be executed by their officials thereunto duly authorized. This Amendment is not valid until signed and dated by both Parties.

FLORIDA MEDICAL SCHOOLS QUALITY

NETWORK, INC.

STATE OF FLORIDA, AGENCY FOR

HEALTH CARE ADMINISTRATION

SIGNED

BY:

NAME: NAME:

TITLE: TITLE:

DATE: DATE:

List of Attachments included as part of this Amendment:

Specify Type Number Description Attachment I Exhibit A-4 Revised Deliverables, Financial

Consequences, and Performance Standards (16 pages)

Attachment II-A

Business Associate Agreement (5 pages)

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05C

EVP USF Health, Dean, Morsani College of Medicine

Dr. Charles Lockwood

12/23/2024 | 14:33 EST

Docusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

Chief of Staff

Stefan Grow

12/30/2024

ATTACHMENT I

EXHIBIT A-4

REVISED DELIVERABLES, FINANCIAL CONSEQUENCES, AND PERFORMANCE

STANDARDS

AHCA Contract No. MED216, Exhibit A-4, Page 1 of 16

1.

DELIVERABLE 1

D01: Donor Milk Bank Timeline

SUPPORTING DOCUMENTATION

The Vendor shall submit a timeline that provides a description of the activities and due dates that shall be completed for the Study on the Use of Donor Human Milk as a supplement to newborn care for infants born prematurely and hospitalized within the NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

July 30, 2021 or within five (5) days of execution of this Contract, whichever is sooner

(COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 1 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

2.

DELIVERABLE 2

D02: Donor Human Milk Banks

SUPPORTING DOCUMENTATION

The Vendor shall submit a list of donor human milk banks and companies supplying donor-derived human milk to infants in Florida in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 1, 2021 (COMPLETED)

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 2 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 2 of 16

3.

DELIVERABLE 3

D03: Donor Human Milk Safety

SUPPORTING DOCUMENTATION

The Vendor shall submit an itemized list and description of the safety considerations in utilizing human milk for newborns in the NICU and the adulterants and contaminants that can be transmitted via human milk in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 17, 2021 (COMPLETED)

AMOUNT

$115,988.33

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 3 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

4.

DELIVERABLE 4

D04: Donor Human Milk Data

SUPPORTING DOCUMENTATION

The Vendor shall submit data showing the use by Florida hospitals of donor human milk made available via donor human milk banks and the related health outcomes and achieved cost-savings for both Medicaid and commercial payors regarding newborn care within a NICU in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.33

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 4 in the time and manner specified in accordance with

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 3 of 16

5.

DELIVERABLE 5

D05: Donor Human Milk Data Recommendations

SUPPORTING DOCUMENTATION

The Vendor shall submit recommendations of best practices which must address, at a minimum:

the operation of a donor human milk tissue bank that facilitates the donation, processing and distribution of donor human milk tissue and donor human milk tissue derivatives; procedures for donation and distribution of donor human milk tissue and donor human milk tissue derivatives; and testing of donor human milk tissue and donor human milk tissue derivatives before donation, processing, and distribution to ensure the absence of adulterants and other contaminants, in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.a.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 24, 2021 (COMPLETED)

AMOUNT

$115,988.34

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with Attachment I, Scope of Services, Section II., Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.a.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 5 in the time and manner specified in accordance with

6.

DELIVERABLE 6

Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report that in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

November 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$118,222.20

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 6 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 4 of 16

7.

DELIVERABLE 7

Final Draft Sickle Cell Disease Study Report

SUPPORTING DOCUMENTATION

The Vendor shall submit a draft sickle cell disease study report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

December 1, 2022, or as otherwise approved by the Agency. (COMPLETED)

AMOUNT

$78,814.80

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 7 in the time and manner specified in accordance with

8.

DELIVERABLE 8

Criteria for Florida Centers of Excellence for Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

2/10/2023 (COMPLETED)

AMOUNT

$9,755.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 8 in the time and manner specified in accordance with

9. DELIVERABLE 9

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 5 of 16

11.

DELIVERABLE 11

Performance Measures for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

Provider Education on Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/28/2023 (COMPLETED)

AMOUNT

$10,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 9 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

10.

DELIVERABLE 10

Preferred Drug List for Treating Patients with Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

3/31/2023 (COMPLETED)

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1..

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 10 in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 6 of 16

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

4/21/2023 (COMPLETED)

AMOUNT

$8,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 11 in the time and manner specified in accordance with

13.

DELIVERABLE 13

Biennial Sickle Cell Disease (SCD) Report Outline (Calendar Years 2022 and 2023)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Report outline for the biennial report due beginning November 1, 2024.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

February 1, 2024 (COMPLETED)

12.

DELIVERABLE 12

External Funding Opportunities for a Florida Consortium of Centers of Excellence in Sickle Cell Disease

SUPPORTING DOCUMENTATION

The Vendor will submit a summary in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.b.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

5/19/2023 (COMPLETED)

AMOUNT

$5,208.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.b.

FINANCIAL CONSEQUENCES

Failure to complete and submit Deliverable 12 in the time and manner specified in accordance with

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 7 of 16

AMOUNT

$20,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 13 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

14.

DELIVERABLE 14

Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2022)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Draft Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B.

Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report; an executive summary; consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 30, 2024 (COMPLETED)

AMOUNT

$200,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1. c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 14 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 8 of 16

15.

DELIVERABLE 15

Final Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2022)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B.

Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report, an executive summary; consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

June 30, 2024 (COMPLETED)

AMOUNT

$30,000.00

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 15 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 9 of 16

16.

DELIVERABLE 16

Draft Maternal and Infant Mortality Report

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a draft Maternal and Infant Mortality Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.d.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

As requested by the Agency. (COMPLETED)

AMOUNT

$225,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.d.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 16 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

17.

DELIVERABLE 17

Final Sickle Cell Disease (SCD) Study Report (Calendar Years 2022 and 2023)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a revised Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.c, and shall include, at minimum, the data analysis for calendar years (CYs) 2022 and 2023 and all of the Agency’s feedback and requested edits.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

October 31, 2024

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 17 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 10 of 16

18.

DELIVERABLE 18

Final Maternal and Infant Mortality Report

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Maternal and Infant Mortality Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.d. and shall include all of the Agency’s feedback and requested edits.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

November 1, 2024

AMOUNT

$25,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.d.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 18 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

19.

DELIVERABLE 19

Data Maintenance and Compliance Report

SUPPORTING DOCUMENTATION

The Vendor shall provide data maintenance and support to the Agency, at no additional cost to the Agency, including but not limited to the following:

• Regular and ongoing monitoring of data maintenance activities.

• Compliance with HIPAA requirements.

• Respond to questions received from the Florida Legislature about the SCD reports.

The Vendor shall submit an attestation that will include the following information:

• An attestation that there have not been any data security breaches.

• An attestation that the Agency’s data has been kept in a secure manner as required by this Contract.

• An attestation of regular monitoring of data maintenance activities.

• An attestation identifying the responsible personnel or teams for data maintenance.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

April 30, 2025 April 30, 2026 April 30, 2027

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 11 of 16

20.

DELIVERABLE 20

Data Request and Verification (January 1, 2024 – December 31, 2024)

SUPPORTING DOCUMENTATION

Part I: The Vendor shall send a detailed e-mail request for the specific data needed to the Agency’s Contract Manager. The request will include, at a minimum, data related to the following:

• Recipient Demographic data.

• Enrollment and Eligibility data.

• Encounter data.

• Medicaid Provider File.

• Pharmacy and Medicaid claims data.

Part II: Upon receipt of all data requested, the Vendor shall conduct an assessment of the data’s internal consistency and reasonableness. A follow-up verification e-mail with the results of the assessment shall be submitted by the Vendor to the Agency’s Contract Manager within thirty (30) calendar days of data delivery. Assessment results shall include a description of the content of data files, including data sources, variables, number of records and date spans, as well as a statement regarding the data’s reasonableness.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 2, 2025

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 20 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction

21.

DELIVERABLE 21

Biennial Sickle Cell Disease (SCD) Report Outline (Calendar Years 2024 and 2025)

SUPPORTING DOCUMENTATION

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section X. Information Technology.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 19 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 12 of 16

The Vendor shall develop and submit a Sickle Cell Disease Report outline for the biennial report due beginning November 1, 2026.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 5, 2025

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 21 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to ten percent (10%) of the total invoiced amount.

22.

DELIVERABLE 22

Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2024)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Draft Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B.

Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report; an executive summary; consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

December 5, 2025

AMOUNT

$120,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1. c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 22 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 13 of 16

23.

DELIVERABLE 23

Data Request and Verification (January 1, 2025 – December 31, 2025)

SUPPORTING DOCUMENTATION

Part I: The Vendor shall send a detailed e-mail request for the specific data needed to the Agency’s Contract Manager. The request will include data related to the following:

• Encounter data.

assessment shall be submitted by the Vendor to the Agency’s Contract Manager within thirty (30) calendar days of data delivery. Assessment results shall include a description of the content of data files, including data sources, variables, number of records and date spans, as well as a statement regarding the data’s reasonableness.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 1, 2026

AMOUNT

N/A

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 23 that meet the minimum quality standards in the

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 14 of 16

24.

DELIVERABLE 24

Final Draft Sickle Cell Disease (SCD) Study Report (Calendar Year 2024 and Calendar Year 2025)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B.

Services Provided by the Vendor, Item 1.c, and shall include, at a minimum, the following components: the purpose of the report, an executive summary; consultations; background fundamentals of sickle cell disease; findings, including the total number of Medicaid recipients diagnosed with Sickle Cell Disease, age and population demographics of people with SCD, health care utilization patterns of Florida Medicaid recipients with SCD, expenditures for Florida Medicaid recipients with SCD, high-utilizers of healthcare services, and clinical treatment programs; and appendix including, methods, pharmaceutical utilization and expenditures, expenditures for medical services in high-utilizers and low utilizers with SCD, and expenditures of pharmaceutical services in low versus high utilizer populations.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

September 18, 2026

AMOUNT

$120,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 24 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 15 of 16

26.

DELIVERABLE 26

Data Request and Verification (January 1, 2026 – December 31, 2026)

SUPPORTING DOCUMENTATION

Part I: The Vendor shall send a detailed e-mail request for the specific data needed to the Agency’s Contract Manager. The request will include, at a minimum, data related to the following:

• Encounter data.

assessment shall be submitted by the Vendor to the Agency’s Contract Manager within thirty (30) calendar days of data delivery. Assessment results shall include a description of the content of data files, including data sources, variables, number of records and date spans, as well as a statement regarding the data’s reasonableness.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

May 1, 2027

AMOUNT

N/A

25.

DELIVERABLE 25

Final Sickle Cell Disease (SCD) Study Report (Calendar Years 2024 and 2025)

SUPPORTING DOCUMENTATION

The Vendor shall develop and submit a revised Sickle Cell Disease Final Report in accordance with Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B. Services Provided by the Vendor, Item 1.c, and shall include, at minimum, the data analysis for calendar years (CYs) 2024 and 2025 and all of the Agency’s feedback and requested edits.

EVALUATION CRITERIA

One hundred percent (100%) of quality criteria checked as “accepted” on the Minimum Quality Standards rubric, commentary grid(s) or other documentation indicating one hundred percent (100%) of requested edits required for deliverable approval were completed.

DUE DATE(S)

October 2, 2026

AMOUNT

$10,000

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 25 that meet the minimum quality standards in the time and manner specified in accordance with this Contract will result in a payment reduction equal to 10 percent of the total invoiced amount.

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Exhibit A-4, Page 16 of 16

PERFORMANCE STANDARDS

The Vendor shall submit the deliverable in accordance with the description provided in Attachment I, Scope of Services, Section II. Manner of Service(s) Provision, Sub-Section B., Services Provided by the Vendor, Item 1.c.

FINANCIAL CONSEQUENCES

Failure to complete and submit the Deliverable 26 that meet the minimum quality standards in the

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

ATTACHMENT II-A

BUSINESS ASSOCIATE AGREEMENT

AHCA Contract No. MED216, Attachment II-A, Page 1 of 5

AHCA Form 2100-0017, Revised (SEP 2024)

The parties to this Attachment agree that the following provisions constitute a business associate agreement for purposes of complying with the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This Attachment is applicable if the Vendor is a business associate within the meaning of the Privacy and Security Regulations, 45 C.F.R. 160 and 164.

The Vendor certifies and agrees as to abide by the following:

1. Definitions. Unless specifically stated in this Attachment, the definition of the terms contained herein shall have the same meaning and effect as defined in 45 C.F.R. 160 and 164.

a. Protected Health Information. For purposes of this Attachment, protected health information shall have the same meaning and effect as defined in 45 C.F.R. 160 and 164, limited to the information created, received, maintained or transmitted by the Vendor from, or on behalf of, the Agency.

b. Electronic Protected Health Information (e-PHI). For purposes of this Attachment, electronic protected health information shall have the same meaning and effect as defined in 45 C.F.R. 160 and 164 (The Security Rule), limited to the electronic information created, received, maintained or transmitted by the Vendor from, or on behalf of, the Agency.

c. Security Incident. For purposes of this Attachment, security incident means the attempted or successful unauthorized access, use, disclosure, modification, or destruction of information or interference with system operations in an information system and includes any event resulting in computer systems, networks, or data being viewed, manipulated, damaged, destroyed or made inaccessible by an unauthorized activity.

d. Confidentiality. For the purposes of this Attachment, confidentiality refers to when electronic protected health information is not made available or disclosed to unauthorized persons or processes.

e. Integrity. For the purposes of this Attachment, integrity means that electronic protected health information has not been altered or destroyed in an unauthorized manner.

f. Availability. For the purposes of this Attachment, availability refers to electronic health information remaining accessible and usable upon demand by an authorized person.

2. Applicability of HITECH and HIPAA Privacy Rule and Security Rule Provisions. As provided by federal law, Title XIII of the American Recovery and Reinvestment Act of 2009 (ARRA), also known as the Health Information Technology Economic ad Clinical Health (HITECH) Act, requires a Business Associate (Vendor) that contracts with the Agency, a HIPAA covered entity, to comply with the provisions of the HIPAA Privacy and Security Rules (45 C.F.R. 160 and 164) and comply with 45 C.F.R. 162 as applicable.

3. Use and Disclosure of Protected Health Information. The Vendor shall comply with the provisions of 45 CFR 164.504(e)(2)(ii). The Vendor shall not use or disclose protected

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Attachment II-A, Page 2 of 5 health information other than as permitted by this Contract or by federal and state law. The sale of protected health information or any components thereof is prohibited except as provided in 45 CFR 164.502(a)(5). The Vendor will use appropriate safeguards to prevent the use or disclosure of protected health information for any purpose not in conformity with this Contract and federal and state law. The Vendor will implement administrative, physical, and technical safeguards that reasonably and appropriately protect the confidentiality, integrity, and availability of electronic protected health information the Vendor creates, receives, maintains, or transmits on behalf of the Agency.

4. Use and Disclosure of Information for Management, Administration, and Legal Responsibilities. The Vendor is permitted to use and disclose protected health information received from the Agency for the proper management and administration of the Vendor or to carry out the legal responsibilities of the Vendor, in accordance with 45 C.F.R.

164.504(e)(4). Such disclosure is only permissible where required by law, or where the Vendor obtains reasonable assurances from the person to whom the protected health information is disclosed that: (1) the protected health information will be held confidentially,

(2) the protected health information will be used or further disclosed only as required by law or for the purposes for which it was disclosed to the person, and (3) the person notifies the Vendor of any instance of which it is aware in which the confidentiality of the protected health information has been breached.

5. Disclosure to Third Parties. The Vendor will not divulge, disclose, or communicate protected health information to any third party for any purpose not in conformity with this Contract without prior written approval from the Agency. The Vendor shall ensure that any agent, including a subcontractor, to whom it provides protected health information received from, or created or received by the Vendor on behalf of the Agency, agrees to the same terms, conditions, and restrictions that apply to the Vendor with respect to protected health information. The Vendor’s subcontracts shall fully comply with the requirements of 45 CFR 164.314(a)(2)(iii).

6. Access to Information. The Vendor shall make protected health information available in accordance with federal and state law, including providing a right of access to persons who are the subjects of the protected health information in accordance with 45 C.F.R.164.524.

7. Amendment and Incorporation of Amendments. The Vendor shall make protected health information available for amendment and to incorporate any amendments to the protected health information in accordance with 45 C.F.R. 164.526.

8. Accounting for Disclosures. The Vendor shall make protected health information available as required to provide an accounting of disclosures in accordance with 45 C.F.R. 164.528.

The Vendor shall document all disclosures of protected health information as needed for the Agency to respond to a request for an accounting of disclosures in accordance with 45 C.F.R. 164.528.

9. Privacy Protection. The Vendor shall permit an individual to request a restriction on the use and disclosure of protected health information about the individual to carry out treatment, payment, or health care operations; and disclosures permitted under 164.510(b) in accordance with 45 C.F.R. 164.522. The Vendor shall permit an individual

Docusign Envelope ID: D475DA1F-FC7F-4AA6-B2D9-714BA313B05CDocusign Envelope ID: 67C76E11-14D8-4EA8-A700-9A0722CEBCDB

AHCA Contract No. MED216, Attachment II-A, Page 3 of 5 to request to receive communications of protected health information from the Vendor by alternative means or at alternative locations in accordance with 45 C.F.R. 164.522.

10. Access to Books and Records. The Vendor shall make its internal practices, books, and records relating to the use and disclosure of protected health information received from, or created or received by the Vendor on behalf of the Agency, available to the Secretary of the Department of Health and Human Services (“HHS”) or the Secretary’s designee for purposes of determining compliance with the HHS Privacy Regulations.

11. Reporting. The Vendor shall make a good faith effort to identify any use or disclosure, or loss of confidentiality, integrity, or availability, of protected health information, or e-PHI, not provided for in this Contract.

a. To Agency. The Vendor will report to the Agency in the manner and format obtained from the Contract Manager or Agency contact, within ten (10) business days of discovery, any use or disclosure, or loss of confidentiality, integrity, or availability, of protected health information, or e-PHI, not provided for in this Contract of which the Vendor is aware.